Regulus Therapeutics reported $0 in Sales Revenues for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Alnylam Pharmaceuticals ALNY:US $ 213.26M 45.28M
Astrazeneca AZN:US $ 11390M 621M
AstraZeneca AZN:LN 11390M 621M
Biogen BIIB:US $ 2531.8M 202M
Celldex Therapeutics CLDX:US $ 0.17M 0.16M
Gilead Sciences GILD:US $ 6590M 654M
GlaxoSmithKline GSK:LN 9780M 253M
Intercept Pharmaceuticals ICPT:US $ 88.58M 3.82M
Intrexon XON:US $ 32.02M 7.8M
Lexicon Pharmaceuticals LXRX:US $ 0.04M 0.02M
Ligand Pharmaceuticals LGND:US $ 45.69M 26.78M
Merk MRK:US $ 15901M 2380M
Sangamo Biosciences SGMO:US $ 28.23M 0.24M
Takeda 4502:JP Y 873289M 28005M
YTE INCY:US $ 733.24M 129.62M